Pharma & Healthcare
Global Bevacizumab Generics Market Research Report 2026
- Mar 17, 26
- ID: 741379
- Pages: 120
- Figures: 119
- Views: 2
This report delivers a comprehensive overview of the global Bevacizumab Generics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bevacizumab Generics. The Bevacizumab Generics market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Bevacizumab Generics market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Bevacizumab Generics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Amneal Pharmaceuticals
Amgen
Celltrion Healthcare
Pfizer
Qilu Pharma
Chia Tai Tianqing
Jiangsu Hengrui Pharmaceuticals
Innovent
Bio-Thera Solutions
SinoCellTech
Shanghai Henlius Biotech
Zhejiang Beta Pharma
Segment by Type
100mg per Vial
400mg per Vial
by Application
Hospital and Clinic
Retail Pharmacies
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Bevacizumab Generics manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Bevacizumab Generics sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Bevacizumab Generics market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Bevacizumab Generics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Amneal Pharmaceuticals
Amgen
Celltrion Healthcare
Pfizer
Qilu Pharma
Chia Tai Tianqing
Jiangsu Hengrui Pharmaceuticals
Innovent
Bio-Thera Solutions
SinoCellTech
Shanghai Henlius Biotech
Zhejiang Beta Pharma
Segment by Type
100mg per Vial
400mg per Vial
by Application
Hospital and Clinic
Retail Pharmacies
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Bevacizumab Generics manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Bevacizumab Generics sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Bevacizumab Generics Market Overview
1.1 Product Definition
1.2 Bevacizumab Generics by Type
1.2.1 Global Bevacizumab Generics Market Value by Type: 2025 vs 2032
1.2.2 100mg per Vial
1.2.3 400mg per Vial
1.3 Bevacizumab Generics by Application
1.3.1 Global Bevacizumab Generics Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Bevacizumab Generics Market Size Estimates and Forecasts
1.4.1 Global Bevacizumab Generics Revenue 2021–2032
1.4.2 Global Bevacizumab Generics Sales 2021–2032
1.4.3 Global Bevacizumab Generics Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Bevacizumab Generics Market Competition by Manufacturers
2.1 Global Bevacizumab Generics Sales Market Share by Manufacturers (2021–2026)
2.2 Global Bevacizumab Generics Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Bevacizumab Generics Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Bevacizumab Generics, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Bevacizumab Generics, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Bevacizumab Generics, Product Types and Applications
2.7 Global Key Manufacturers of Bevacizumab Generics, Date of Entry into the Industry
2.8 Global Bevacizumab Generics Market Competitive Situation and Trends
2.8.1 Global Bevacizumab Generics Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Bevacizumab Generics Players Market Share by Revenue
2.8.3 Global Bevacizumab Generics Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Bevacizumab Generics Market Scenario by Region
3.1 Global Bevacizumab Generics Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Bevacizumab Generics Sales by Region: 2021–2032
3.2.1 Global Bevacizumab Generics Sales by Region: 2021–2026
3.2.2 Global Bevacizumab Generics Sales by Region: 2027–2032
3.3 Global Bevacizumab Generics Revenue by Region: 2021–2032
3.3.1 Global Bevacizumab Generics Revenue by Region: 2021–2026
3.3.2 Global Bevacizumab Generics Revenue by Region: 2027–2032
3.4 North America Bevacizumab Generics Market Facts & Figures by Country
3.4.1 North America Bevacizumab Generics Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Bevacizumab Generics Sales by Country (2021–2032)
3.4.3 North America Bevacizumab Generics Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bevacizumab Generics Market Facts & Figures by Country
3.5.1 Europe Bevacizumab Generics Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Bevacizumab Generics Sales by Country (2021–2032)
3.5.3 Europe Bevacizumab Generics Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bevacizumab Generics Market Facts & Figures by Region
3.6.1 Asia Pacific Bevacizumab Generics Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Bevacizumab Generics Sales by Region (2021–2032)
3.6.3 Asia Pacific Bevacizumab Generics Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bevacizumab Generics Market Facts & Figures by Country
3.7.1 Latin America Bevacizumab Generics Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Bevacizumab Generics Sales by Country (2021–2032)
3.7.3 Latin America Bevacizumab Generics Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bevacizumab Generics Market Facts & Figures by Country
3.8.1 Middle East and Africa Bevacizumab Generics Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Bevacizumab Generics Sales by Country (2021–2032)
3.8.3 Middle East and Africa Bevacizumab Generics Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bevacizumab Generics Sales by Type (2021–2032)
4.1.1 Global Bevacizumab Generics Sales by Type (2021–2026)
4.1.2 Global Bevacizumab Generics Sales by Type (2027–2032)
4.1.3 Global Bevacizumab Generics Sales Market Share by Type (2021–2032)
4.2 Global Bevacizumab Generics Revenue by Type (2021–2032)
4.2.1 Global Bevacizumab Generics Revenue by Type (2021–2026)
4.2.2 Global Bevacizumab Generics Revenue by Type (2027–2032)
4.2.3 Global Bevacizumab Generics Revenue Market Share by Type (2021–2032)
4.3 Global Bevacizumab Generics Price by Type (2021–2032)
5 Segment by Application
5.1 Global Bevacizumab Generics Sales by Application (2021–2032)
5.1.1 Global Bevacizumab Generics Sales by Application (2021–2026)
5.1.2 Global Bevacizumab Generics Sales by Application (2027–2032)
5.1.3 Global Bevacizumab Generics Sales Market Share by Application (2021–2032)
5.2 Global Bevacizumab Generics Revenue by Application (2021–2032)
5.2.1 Global Bevacizumab Generics Revenue by Application (2021–2026)
5.2.2 Global Bevacizumab Generics Revenue by Application (2027–2032)
5.2.3 Global Bevacizumab Generics Revenue Market Share by Application (2021–2032)
5.3 Global Bevacizumab Generics Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Amneal Pharmaceuticals
6.1.1 Amneal Pharmaceuticals Company Information
6.1.2 Amneal Pharmaceuticals Description and Business Overview
6.1.3 Amneal Pharmaceuticals Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Amneal Pharmaceuticals Bevacizumab Generics Product Portfolio
6.1.5 Amneal Pharmaceuticals Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Company Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Amgen Bevacizumab Generics Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Celltrion Healthcare
6.3.1 Celltrion Healthcare Company Information
6.3.2 Celltrion Healthcare Description and Business Overview
6.3.3 Celltrion Healthcare Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Celltrion Healthcare Bevacizumab Generics Product Portfolio
6.3.5 Celltrion Healthcare Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Pfizer Bevacizumab Generics Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Qilu Pharma
6.5.1 Qilu Pharma Company Information
6.5.2 Qilu Pharma Description and Business Overview
6.5.3 Qilu Pharma Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Qilu Pharma Bevacizumab Generics Product Portfolio
6.5.5 Qilu Pharma Recent Developments/Updates
6.6 Chia Tai Tianqing
6.6.1 Chia Tai Tianqing Company Information
6.6.2 Chia Tai Tianqing Description and Business Overview
6.6.3 Chia Tai Tianqing Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Chia Tai Tianqing Bevacizumab Generics Product Portfolio
6.6.5 Chia Tai Tianqing Recent Developments/Updates
6.7 Jiangsu Hengrui Pharmaceuticals
6.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.7.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.7.3 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product Portfolio
6.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.8 Innovent
6.8.1 Innovent Company Information
6.8.2 Innovent Description and Business Overview
6.8.3 Innovent Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Innovent Bevacizumab Generics Product Portfolio
6.8.5 Innovent Recent Developments/Updates
6.9 Bio-Thera Solutions
6.9.1 Bio-Thera Solutions Company Information
6.9.2 Bio-Thera Solutions Description and Business Overview
6.9.3 Bio-Thera Solutions Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Bio-Thera Solutions Bevacizumab Generics Product Portfolio
6.9.5 Bio-Thera Solutions Recent Developments/Updates
6.10 SinoCellTech
6.10.1 SinoCellTech Company Information
6.10.2 SinoCellTech Description and Business Overview
6.10.3 SinoCellTech Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 SinoCellTech Bevacizumab Generics Product Portfolio
6.10.5 SinoCellTech Recent Developments/Updates
6.11 Shanghai Henlius Biotech
6.11.1 Shanghai Henlius Biotech Company Information
6.11.2 Shanghai Henlius Biotech Description and Business Overview
6.11.3 Shanghai Henlius Biotech Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Shanghai Henlius Biotech Bevacizumab Generics Product Portfolio
6.11.5 Shanghai Henlius Biotech Recent Developments/Updates
6.12 Zhejiang Beta Pharma
6.12.1 Zhejiang Beta Pharma Company Information
6.12.2 Zhejiang Beta Pharma Description and Business Overview
6.12.3 Zhejiang Beta Pharma Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Zhejiang Beta Pharma Bevacizumab Generics Product Portfolio
6.12.5 Zhejiang Beta Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bevacizumab Generics Industry Chain Analysis
7.2 Bevacizumab Generics Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bevacizumab Generics Production Mode & Process Analysis
7.4 Bevacizumab Generics Sales and Marketing
7.4.1 Bevacizumab Generics Sales Channels
7.4.2 Bevacizumab Generics Distributors
7.5 Bevacizumab Generics Customer Analysis
8 Bevacizumab Generics Market Dynamics
8.1 Bevacizumab Generics Industry Trends
8.2 Bevacizumab Generics Market Drivers
8.3 Bevacizumab Generics Market Challenges
8.4 Bevacizumab Generics Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Bevacizumab Generics by Type
1.2.1 Global Bevacizumab Generics Market Value by Type: 2025 vs 2032
1.2.2 100mg per Vial
1.2.3 400mg per Vial
1.3 Bevacizumab Generics by Application
1.3.1 Global Bevacizumab Generics Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Bevacizumab Generics Market Size Estimates and Forecasts
1.4.1 Global Bevacizumab Generics Revenue 2021–2032
1.4.2 Global Bevacizumab Generics Sales 2021–2032
1.4.3 Global Bevacizumab Generics Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Bevacizumab Generics Market Competition by Manufacturers
2.1 Global Bevacizumab Generics Sales Market Share by Manufacturers (2021–2026)
2.2 Global Bevacizumab Generics Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Bevacizumab Generics Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Bevacizumab Generics, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Bevacizumab Generics, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Bevacizumab Generics, Product Types and Applications
2.7 Global Key Manufacturers of Bevacizumab Generics, Date of Entry into the Industry
2.8 Global Bevacizumab Generics Market Competitive Situation and Trends
2.8.1 Global Bevacizumab Generics Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Bevacizumab Generics Players Market Share by Revenue
2.8.3 Global Bevacizumab Generics Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Bevacizumab Generics Market Scenario by Region
3.1 Global Bevacizumab Generics Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Bevacizumab Generics Sales by Region: 2021–2032
3.2.1 Global Bevacizumab Generics Sales by Region: 2021–2026
3.2.2 Global Bevacizumab Generics Sales by Region: 2027–2032
3.3 Global Bevacizumab Generics Revenue by Region: 2021–2032
3.3.1 Global Bevacizumab Generics Revenue by Region: 2021–2026
3.3.2 Global Bevacizumab Generics Revenue by Region: 2027–2032
3.4 North America Bevacizumab Generics Market Facts & Figures by Country
3.4.1 North America Bevacizumab Generics Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Bevacizumab Generics Sales by Country (2021–2032)
3.4.3 North America Bevacizumab Generics Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bevacizumab Generics Market Facts & Figures by Country
3.5.1 Europe Bevacizumab Generics Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Bevacizumab Generics Sales by Country (2021–2032)
3.5.3 Europe Bevacizumab Generics Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bevacizumab Generics Market Facts & Figures by Region
3.6.1 Asia Pacific Bevacizumab Generics Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Bevacizumab Generics Sales by Region (2021–2032)
3.6.3 Asia Pacific Bevacizumab Generics Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bevacizumab Generics Market Facts & Figures by Country
3.7.1 Latin America Bevacizumab Generics Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Bevacizumab Generics Sales by Country (2021–2032)
3.7.3 Latin America Bevacizumab Generics Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bevacizumab Generics Market Facts & Figures by Country
3.8.1 Middle East and Africa Bevacizumab Generics Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Bevacizumab Generics Sales by Country (2021–2032)
3.8.3 Middle East and Africa Bevacizumab Generics Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bevacizumab Generics Sales by Type (2021–2032)
4.1.1 Global Bevacizumab Generics Sales by Type (2021–2026)
4.1.2 Global Bevacizumab Generics Sales by Type (2027–2032)
4.1.3 Global Bevacizumab Generics Sales Market Share by Type (2021–2032)
4.2 Global Bevacizumab Generics Revenue by Type (2021–2032)
4.2.1 Global Bevacizumab Generics Revenue by Type (2021–2026)
4.2.2 Global Bevacizumab Generics Revenue by Type (2027–2032)
4.2.3 Global Bevacizumab Generics Revenue Market Share by Type (2021–2032)
4.3 Global Bevacizumab Generics Price by Type (2021–2032)
5 Segment by Application
5.1 Global Bevacizumab Generics Sales by Application (2021–2032)
5.1.1 Global Bevacizumab Generics Sales by Application (2021–2026)
5.1.2 Global Bevacizumab Generics Sales by Application (2027–2032)
5.1.3 Global Bevacizumab Generics Sales Market Share by Application (2021–2032)
5.2 Global Bevacizumab Generics Revenue by Application (2021–2032)
5.2.1 Global Bevacizumab Generics Revenue by Application (2021–2026)
5.2.2 Global Bevacizumab Generics Revenue by Application (2027–2032)
5.2.3 Global Bevacizumab Generics Revenue Market Share by Application (2021–2032)
5.3 Global Bevacizumab Generics Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Amneal Pharmaceuticals
6.1.1 Amneal Pharmaceuticals Company Information
6.1.2 Amneal Pharmaceuticals Description and Business Overview
6.1.3 Amneal Pharmaceuticals Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Amneal Pharmaceuticals Bevacizumab Generics Product Portfolio
6.1.5 Amneal Pharmaceuticals Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Company Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Amgen Bevacizumab Generics Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Celltrion Healthcare
6.3.1 Celltrion Healthcare Company Information
6.3.2 Celltrion Healthcare Description and Business Overview
6.3.3 Celltrion Healthcare Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Celltrion Healthcare Bevacizumab Generics Product Portfolio
6.3.5 Celltrion Healthcare Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Pfizer Bevacizumab Generics Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Qilu Pharma
6.5.1 Qilu Pharma Company Information
6.5.2 Qilu Pharma Description and Business Overview
6.5.3 Qilu Pharma Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Qilu Pharma Bevacizumab Generics Product Portfolio
6.5.5 Qilu Pharma Recent Developments/Updates
6.6 Chia Tai Tianqing
6.6.1 Chia Tai Tianqing Company Information
6.6.2 Chia Tai Tianqing Description and Business Overview
6.6.3 Chia Tai Tianqing Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Chia Tai Tianqing Bevacizumab Generics Product Portfolio
6.6.5 Chia Tai Tianqing Recent Developments/Updates
6.7 Jiangsu Hengrui Pharmaceuticals
6.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.7.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.7.3 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product Portfolio
6.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.8 Innovent
6.8.1 Innovent Company Information
6.8.2 Innovent Description and Business Overview
6.8.3 Innovent Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Innovent Bevacizumab Generics Product Portfolio
6.8.5 Innovent Recent Developments/Updates
6.9 Bio-Thera Solutions
6.9.1 Bio-Thera Solutions Company Information
6.9.2 Bio-Thera Solutions Description and Business Overview
6.9.3 Bio-Thera Solutions Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Bio-Thera Solutions Bevacizumab Generics Product Portfolio
6.9.5 Bio-Thera Solutions Recent Developments/Updates
6.10 SinoCellTech
6.10.1 SinoCellTech Company Information
6.10.2 SinoCellTech Description and Business Overview
6.10.3 SinoCellTech Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 SinoCellTech Bevacizumab Generics Product Portfolio
6.10.5 SinoCellTech Recent Developments/Updates
6.11 Shanghai Henlius Biotech
6.11.1 Shanghai Henlius Biotech Company Information
6.11.2 Shanghai Henlius Biotech Description and Business Overview
6.11.3 Shanghai Henlius Biotech Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Shanghai Henlius Biotech Bevacizumab Generics Product Portfolio
6.11.5 Shanghai Henlius Biotech Recent Developments/Updates
6.12 Zhejiang Beta Pharma
6.12.1 Zhejiang Beta Pharma Company Information
6.12.2 Zhejiang Beta Pharma Description and Business Overview
6.12.3 Zhejiang Beta Pharma Bevacizumab Generics Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Zhejiang Beta Pharma Bevacizumab Generics Product Portfolio
6.12.5 Zhejiang Beta Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bevacizumab Generics Industry Chain Analysis
7.2 Bevacizumab Generics Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bevacizumab Generics Production Mode & Process Analysis
7.4 Bevacizumab Generics Sales and Marketing
7.4.1 Bevacizumab Generics Sales Channels
7.4.2 Bevacizumab Generics Distributors
7.5 Bevacizumab Generics Customer Analysis
8 Bevacizumab Generics Market Dynamics
8.1 Bevacizumab Generics Industry Trends
8.2 Bevacizumab Generics Market Drivers
8.3 Bevacizumab Generics Market Challenges
8.4 Bevacizumab Generics Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Bevacizumab Generics Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Bevacizumab Generics Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Bevacizumab Generics Market Competitive Situation by Manufacturers in 2025
Table 4. Global Bevacizumab Generics Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Bevacizumab Generics Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Bevacizumab Generics Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Bevacizumab Generics Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Bevacizumab Generics Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Bevacizumab Generics, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Bevacizumab Generics, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Bevacizumab Generics, Product Types and Applications
Table 12. Global Key Manufacturers of Bevacizumab Generics, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Bevacizumab Generics Companies by Tier (Tier 1, Tier 2, Tier 3), based on Bevacizumab Generics Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Bevacizumab Generics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Bevacizumab Generics Sales by Region (K Dose), 2021–2026
Table 18. Global Bevacizumab Generics Sales Market Share by Region (2021–2026)
Table 19. Global Bevacizumab Generics Sales by Region (K Dose), 2027–2032
Table 20. Global Bevacizumab Generics Sales Market Share by Region (2027–2032)
Table 21. Global Bevacizumab Generics Revenue by Region (US$ Million), 2021–2026
Table 22. Global Bevacizumab Generics Revenue Market Share by Region (2021–2026)
Table 23. Global Bevacizumab Generics Revenue by Region (US$ Million), 2027–2032
Table 24. Global Bevacizumab Generics Revenue Market Share by Region (2027–2032)
Table 25. North America Bevacizumab Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Bevacizumab Generics Sales by Country (K Dose), 2021–2026
Table 27. North America Bevacizumab Generics Sales by Country (K Dose), 2027–2032
Table 28. North America Bevacizumab Generics Revenue by Country (US$ Million), 2021–2026
Table 29. North America Bevacizumab Generics Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Bevacizumab Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Bevacizumab Generics Sales by Country (K Dose), 2021–2026
Table 32. Europe Bevacizumab Generics Sales by Country (K Dose), 2027–2032
Table 33. Europe Bevacizumab Generics Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Bevacizumab Generics Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Bevacizumab Generics Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Bevacizumab Generics Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Bevacizumab Generics Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Bevacizumab Generics Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Bevacizumab Generics Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Bevacizumab Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Bevacizumab Generics Sales by Country (K Dose), 2021–2026
Table 42. Latin America Bevacizumab Generics Sales by Country (K Dose), 2027–2032
Table 43. Latin America Bevacizumab Generics Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Bevacizumab Generics Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Bevacizumab Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Bevacizumab Generics Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Bevacizumab Generics Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Bevacizumab Generics Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Bevacizumab Generics Revenue by Country (US$ Million), 2027–2032
Table 50. Global Bevacizumab Generics Sales (K Dose) by Type (2021–2026)
Table 51. Global Bevacizumab Generics Sales (K Dose) by Type (2027–2032)
Table 52. Global Bevacizumab Generics Sales Market Share by Type (2021–2026)
Table 53. Global Bevacizumab Generics Sales Market Share by Type (2027–2032)
Table 54. Global Bevacizumab Generics Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Bevacizumab Generics Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Bevacizumab Generics Revenue Market Share by Type (2021–2026)
Table 57. Global Bevacizumab Generics Revenue Market Share by Type (2027–2032)
Table 58. Global Bevacizumab Generics Price (US$/Dose) by Type (2021–2026)
Table 59. Global Bevacizumab Generics Price (US$/Dose) by Type (2027–2032)
Table 60. Global Bevacizumab Generics Sales (K Dose) by Application (2021–2026)
Table 61. Global Bevacizumab Generics Sales (K Dose) by Application (2027–2032)
Table 62. Global Bevacizumab Generics Sales Market Share by Application (2021–2026)
Table 63. Global Bevacizumab Generics Sales Market Share by Application (2027–2032)
Table 64. Global Bevacizumab Generics Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Bevacizumab Generics Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Bevacizumab Generics Revenue Market Share by Application (2021–2026)
Table 67. Global Bevacizumab Generics Revenue Market Share by Application (2027–2032)
Table 68. Global Bevacizumab Generics Price (US$/Dose) by Application (2021–2026)
Table 69. Global Bevacizumab Generics Price (US$/Dose) by Application (2027–2032)
Table 70. Amneal Pharmaceuticals Company Information
Table 71. Amneal Pharmaceuticals Description and Business Overview
Table 72. Amneal Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Amneal Pharmaceuticals Bevacizumab Generics Product
Table 74. Amneal Pharmaceuticals Recent Developments/Updates
Table 75. Amgen Company Information
Table 76. Amgen Description and Business Overview
Table 77. Amgen Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Amgen Bevacizumab Generics Product
Table 79. Amgen Recent Developments/Updates
Table 80. Celltrion Healthcare Company Information
Table 81. Celltrion Healthcare Description and Business Overview
Table 82. Celltrion Healthcare Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. Celltrion Healthcare Bevacizumab Generics Product
Table 84. Celltrion Healthcare Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Pfizer Bevacizumab Generics Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Qilu Pharma Company Information
Table 91. Qilu Pharma Description and Business Overview
Table 92. Qilu Pharma Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Qilu Pharma Bevacizumab Generics Product
Table 94. Qilu Pharma Recent Developments/Updates
Table 95. Chia Tai Tianqing Company Information
Table 96. Chia Tai Tianqing Description and Business Overview
Table 97. Chia Tai Tianqing Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Chia Tai Tianqing Bevacizumab Generics Product
Table 99. Chia Tai Tianqing Recent Developments/Updates
Table 100. Jiangsu Hengrui Pharmaceuticals Company Information
Table 101. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 102. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product
Table 104. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 105. Innovent Company Information
Table 106. Innovent Description and Business Overview
Table 107. Innovent Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Innovent Bevacizumab Generics Product
Table 109. Innovent Recent Developments/Updates
Table 110. Bio-Thera Solutions Company Information
Table 111. Bio-Thera Solutions Description and Business Overview
Table 112. Bio-Thera Solutions Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 113. Bio-Thera Solutions Bevacizumab Generics Product
Table 114. Bio-Thera Solutions Recent Developments/Updates
Table 115. SinoCellTech Company Information
Table 116. SinoCellTech Description and Business Overview
Table 117. SinoCellTech Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 118. SinoCellTech Bevacizumab Generics Product
Table 119. SinoCellTech Recent Developments/Updates
Table 120. Shanghai Henlius Biotech Company Information
Table 121. Shanghai Henlius Biotech Description and Business Overview
Table 122. Shanghai Henlius Biotech Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 123. Shanghai Henlius Biotech Bevacizumab Generics Product
Table 124. Shanghai Henlius Biotech Recent Developments/Updates
Table 125. Zhejiang Beta Pharma Company Information
Table 126. Zhejiang Beta Pharma Description and Business Overview
Table 127. Zhejiang Beta Pharma Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 128. Zhejiang Beta Pharma Bevacizumab Generics Product
Table 129. Zhejiang Beta Pharma Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Bevacizumab Generics Distributors List
Table 133. Bevacizumab Generics Customers List
Table 134. Bevacizumab Generics Market Trends
Table 135. Bevacizumab Generics Market Drivers
Table 136. Bevacizumab Generics Market Challenges
Table 137. Bevacizumab Generics Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Product Picture of Bevacizumab Generics
Figure 2. Global Bevacizumab Generics Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Bevacizumab Generics Market Share by Type: 2025 & 2032
Figure 4. 100mg per Vial Product Picture
Figure 5. 400mg per Vial Product Picture
Figure 6. Global Bevacizumab Generics Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Bevacizumab Generics Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Retail Pharmacies
Figure 10. Other
Figure 11. Global Bevacizumab Generics Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Bevacizumab Generics Market Size (US$ Million), 2021–2032
Figure 13. Global Bevacizumab Generics Sales (K Dose), 2021–2032
Figure 14. Global Bevacizumab Generics Average Price (US$/Dose), 2021–2032
Figure 15. Bevacizumab Generics Report Years Considered
Figure 16. Bevacizumab Generics Sales Share by Manufacturers in 2025
Figure 17. Global Bevacizumab Generics Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Bevacizumab Generics Players: Market Share by Revenue in Bevacizumab Generics in 2025
Figure 19. Bevacizumab Generics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Bevacizumab Generics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Bevacizumab Generics Sales Market Share by Country (2021–2032)
Figure 22. North America Bevacizumab Generics Revenue Market Share by Country (2021–2032)
Figure 23. United States Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Bevacizumab Generics Sales Market Share by Country (2021–2032)
Figure 26. Europe Bevacizumab Generics Revenue Market Share by Country (2021–2032)
Figure 27. Germany Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Bevacizumab Generics Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Bevacizumab Generics Revenue Market Share by Region (2021–2032)
Figure 34. China Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Bevacizumab Generics Sales Market Share by Country (2021–2032)
Figure 42. Latin America Bevacizumab Generics Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Bevacizumab Generics Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Bevacizumab Generics Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Bevacizumab Generics by Type (2021–2032)
Figure 53. Global Revenue Market Share of Bevacizumab Generics by Type (2021–2032)
Figure 54. Global Bevacizumab Generics Price (US$/Dose) by Type (2021–2032)
Figure 55. Global Sales Market Share of Bevacizumab Generics by Application (2021–2032)
Figure 56. Global Revenue Market Share of Bevacizumab Generics by Application (2021–2032)
Figure 57. Global Bevacizumab Generics Price (US$/Dose) by Application (2021–2032)
Figure 58. Bevacizumab Generics Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Bevacizumab Generics Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Bevacizumab Generics Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Bevacizumab Generics Market Competitive Situation by Manufacturers in 2025
Table 4. Global Bevacizumab Generics Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Bevacizumab Generics Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Bevacizumab Generics Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Bevacizumab Generics Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Bevacizumab Generics Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Bevacizumab Generics, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Bevacizumab Generics, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Bevacizumab Generics, Product Types and Applications
Table 12. Global Key Manufacturers of Bevacizumab Generics, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Bevacizumab Generics Companies by Tier (Tier 1, Tier 2, Tier 3), based on Bevacizumab Generics Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Bevacizumab Generics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Bevacizumab Generics Sales by Region (K Dose), 2021–2026
Table 18. Global Bevacizumab Generics Sales Market Share by Region (2021–2026)
Table 19. Global Bevacizumab Generics Sales by Region (K Dose), 2027–2032
Table 20. Global Bevacizumab Generics Sales Market Share by Region (2027–2032)
Table 21. Global Bevacizumab Generics Revenue by Region (US$ Million), 2021–2026
Table 22. Global Bevacizumab Generics Revenue Market Share by Region (2021–2026)
Table 23. Global Bevacizumab Generics Revenue by Region (US$ Million), 2027–2032
Table 24. Global Bevacizumab Generics Revenue Market Share by Region (2027–2032)
Table 25. North America Bevacizumab Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Bevacizumab Generics Sales by Country (K Dose), 2021–2026
Table 27. North America Bevacizumab Generics Sales by Country (K Dose), 2027–2032
Table 28. North America Bevacizumab Generics Revenue by Country (US$ Million), 2021–2026
Table 29. North America Bevacizumab Generics Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Bevacizumab Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Bevacizumab Generics Sales by Country (K Dose), 2021–2026
Table 32. Europe Bevacizumab Generics Sales by Country (K Dose), 2027–2032
Table 33. Europe Bevacizumab Generics Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Bevacizumab Generics Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Bevacizumab Generics Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Bevacizumab Generics Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Bevacizumab Generics Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Bevacizumab Generics Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Bevacizumab Generics Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Bevacizumab Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Bevacizumab Generics Sales by Country (K Dose), 2021–2026
Table 42. Latin America Bevacizumab Generics Sales by Country (K Dose), 2027–2032
Table 43. Latin America Bevacizumab Generics Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Bevacizumab Generics Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Bevacizumab Generics Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Bevacizumab Generics Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Bevacizumab Generics Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Bevacizumab Generics Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Bevacizumab Generics Revenue by Country (US$ Million), 2027–2032
Table 50. Global Bevacizumab Generics Sales (K Dose) by Type (2021–2026)
Table 51. Global Bevacizumab Generics Sales (K Dose) by Type (2027–2032)
Table 52. Global Bevacizumab Generics Sales Market Share by Type (2021–2026)
Table 53. Global Bevacizumab Generics Sales Market Share by Type (2027–2032)
Table 54. Global Bevacizumab Generics Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Bevacizumab Generics Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Bevacizumab Generics Revenue Market Share by Type (2021–2026)
Table 57. Global Bevacizumab Generics Revenue Market Share by Type (2027–2032)
Table 58. Global Bevacizumab Generics Price (US$/Dose) by Type (2021–2026)
Table 59. Global Bevacizumab Generics Price (US$/Dose) by Type (2027–2032)
Table 60. Global Bevacizumab Generics Sales (K Dose) by Application (2021–2026)
Table 61. Global Bevacizumab Generics Sales (K Dose) by Application (2027–2032)
Table 62. Global Bevacizumab Generics Sales Market Share by Application (2021–2026)
Table 63. Global Bevacizumab Generics Sales Market Share by Application (2027–2032)
Table 64. Global Bevacizumab Generics Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Bevacizumab Generics Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Bevacizumab Generics Revenue Market Share by Application (2021–2026)
Table 67. Global Bevacizumab Generics Revenue Market Share by Application (2027–2032)
Table 68. Global Bevacizumab Generics Price (US$/Dose) by Application (2021–2026)
Table 69. Global Bevacizumab Generics Price (US$/Dose) by Application (2027–2032)
Table 70. Amneal Pharmaceuticals Company Information
Table 71. Amneal Pharmaceuticals Description and Business Overview
Table 72. Amneal Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Amneal Pharmaceuticals Bevacizumab Generics Product
Table 74. Amneal Pharmaceuticals Recent Developments/Updates
Table 75. Amgen Company Information
Table 76. Amgen Description and Business Overview
Table 77. Amgen Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Amgen Bevacizumab Generics Product
Table 79. Amgen Recent Developments/Updates
Table 80. Celltrion Healthcare Company Information
Table 81. Celltrion Healthcare Description and Business Overview
Table 82. Celltrion Healthcare Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. Celltrion Healthcare Bevacizumab Generics Product
Table 84. Celltrion Healthcare Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Pfizer Bevacizumab Generics Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Qilu Pharma Company Information
Table 91. Qilu Pharma Description and Business Overview
Table 92. Qilu Pharma Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Qilu Pharma Bevacizumab Generics Product
Table 94. Qilu Pharma Recent Developments/Updates
Table 95. Chia Tai Tianqing Company Information
Table 96. Chia Tai Tianqing Description and Business Overview
Table 97. Chia Tai Tianqing Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Chia Tai Tianqing Bevacizumab Generics Product
Table 99. Chia Tai Tianqing Recent Developments/Updates
Table 100. Jiangsu Hengrui Pharmaceuticals Company Information
Table 101. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 102. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product
Table 104. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 105. Innovent Company Information
Table 106. Innovent Description and Business Overview
Table 107. Innovent Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Innovent Bevacizumab Generics Product
Table 109. Innovent Recent Developments/Updates
Table 110. Bio-Thera Solutions Company Information
Table 111. Bio-Thera Solutions Description and Business Overview
Table 112. Bio-Thera Solutions Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 113. Bio-Thera Solutions Bevacizumab Generics Product
Table 114. Bio-Thera Solutions Recent Developments/Updates
Table 115. SinoCellTech Company Information
Table 116. SinoCellTech Description and Business Overview
Table 117. SinoCellTech Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 118. SinoCellTech Bevacizumab Generics Product
Table 119. SinoCellTech Recent Developments/Updates
Table 120. Shanghai Henlius Biotech Company Information
Table 121. Shanghai Henlius Biotech Description and Business Overview
Table 122. Shanghai Henlius Biotech Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 123. Shanghai Henlius Biotech Bevacizumab Generics Product
Table 124. Shanghai Henlius Biotech Recent Developments/Updates
Table 125. Zhejiang Beta Pharma Company Information
Table 126. Zhejiang Beta Pharma Description and Business Overview
Table 127. Zhejiang Beta Pharma Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 128. Zhejiang Beta Pharma Bevacizumab Generics Product
Table 129. Zhejiang Beta Pharma Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Bevacizumab Generics Distributors List
Table 133. Bevacizumab Generics Customers List
Table 134. Bevacizumab Generics Market Trends
Table 135. Bevacizumab Generics Market Drivers
Table 136. Bevacizumab Generics Market Challenges
Table 137. Bevacizumab Generics Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Product Picture of Bevacizumab Generics
Figure 2. Global Bevacizumab Generics Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Bevacizumab Generics Market Share by Type: 2025 & 2032
Figure 4. 100mg per Vial Product Picture
Figure 5. 400mg per Vial Product Picture
Figure 6. Global Bevacizumab Generics Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Bevacizumab Generics Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Retail Pharmacies
Figure 10. Other
Figure 11. Global Bevacizumab Generics Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Bevacizumab Generics Market Size (US$ Million), 2021–2032
Figure 13. Global Bevacizumab Generics Sales (K Dose), 2021–2032
Figure 14. Global Bevacizumab Generics Average Price (US$/Dose), 2021–2032
Figure 15. Bevacizumab Generics Report Years Considered
Figure 16. Bevacizumab Generics Sales Share by Manufacturers in 2025
Figure 17. Global Bevacizumab Generics Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Bevacizumab Generics Players: Market Share by Revenue in Bevacizumab Generics in 2025
Figure 19. Bevacizumab Generics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Bevacizumab Generics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Bevacizumab Generics Sales Market Share by Country (2021–2032)
Figure 22. North America Bevacizumab Generics Revenue Market Share by Country (2021–2032)
Figure 23. United States Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Bevacizumab Generics Sales Market Share by Country (2021–2032)
Figure 26. Europe Bevacizumab Generics Revenue Market Share by Country (2021–2032)
Figure 27. Germany Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Bevacizumab Generics Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Bevacizumab Generics Revenue Market Share by Region (2021–2032)
Figure 34. China Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Bevacizumab Generics Sales Market Share by Country (2021–2032)
Figure 42. Latin America Bevacizumab Generics Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Bevacizumab Generics Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Bevacizumab Generics Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Bevacizumab Generics Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Bevacizumab Generics by Type (2021–2032)
Figure 53. Global Revenue Market Share of Bevacizumab Generics by Type (2021–2032)
Figure 54. Global Bevacizumab Generics Price (US$/Dose) by Type (2021–2032)
Figure 55. Global Sales Market Share of Bevacizumab Generics by Application (2021–2032)
Figure 56. Global Revenue Market Share of Bevacizumab Generics by Application (2021–2032)
Figure 57. Global Bevacizumab Generics Price (US$/Dose) by Application (2021–2032)
Figure 58. Bevacizumab Generics Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232